Feb 24, 2023
On February 1, Amjevita became the first Humira biosimilar to be made available in the U.S., which is great news for employers and their employees.
Humira, a medicine used by more than a million patients living with certain serious inflammatory diseases,* is one of the most expensive brand-name drugs in the country. The arrival of Amjevita will help significantly reduce drug costs for our clients and their workforces.
Amjevita is one of many Humira biosimilars expected to launch in 2023. As more biosimilar products come to market, CareFirst will continue to evaluate their formulary strategy so they can bring their clients the lowest net cost solution.
Formulary Details
- Amjevita will be covered on CareFirst commercial formularies (F1, F2, F3, F4) as a non-preferred specialty drug. It will be Tier 3 or Tier 5, depending on the formulary.
- Formulary documents will be updated on March 1.
* Amjevita™ (Adalimumab-Atto), First Biosimilar to Humira, Now Available in the United States, Cision PR Wire, Amgen, AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES (prnewswire.com). Accessed Feb. 2023.
